All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BIO89-100
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Similar reductions in liver fat, ALT and triglycerides between biopsy-confirmed NASH and PNASH patients treated with BIO89-100 and their similar baseline characteristics underscored the consistency across these two sub-populations of patients enrolled in the trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BIO89-100
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Clinical data from its Phase 1b/2a study evaluating BIO89-100, a long-acting glycoPEGylated FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH) will be presented in a late-breaking poster at The Liver Meeting Digital Experience™ 2020 of the AASLD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BIO89-100
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2020
Details:
Company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BIO89-100
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 06, 2020
Details:
89bio intends to use the net proceeds of the offering to accelerate and support its BIO89-100 programs in nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), for the manufacture and scale up of BIO89-100, and for other general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cell therapy products
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
European Medicines Agency (EMA) has given a positive scientific advice on its clinical development, pharmaco-toxicological and production strategy plans. With this positive scientific advice, GoLiver Therapeutics has reached an important milestone in its clinical roadmap.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BIO89-100
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
Details:
The company closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DCR-A1AT
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
The Company expects to dose the first patient in the second half of 2020.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
